Trade Names:Alocril- Solution, ophthalmic 2% (20 mg/mL)
Trade Names:Tilade- Aerosol 1.75 mg/actuation
Inhibits release of mediators from inflammatory cell types associated with asthma, including histamine from mast cells and betaglucuronidase from macrophages. May also suppress local production of leukotrienes and prostaglandins. Inhibits development of bronchoconstriction responses to inhaled antigen and other challenges such as cold air.
Nedocromil sodium bioavailability is 8% to 17%, C max is 1.6 to 2.8 ng/mL, and T max is 5 to 90 min.
Plasma protein binding is approximately 89%.
Nedocromil sodium is not metabolized.
Nedocromil is eliminated unchanged in urine 64% and feces 36%. The t ½ is 1.5 to 3.3 h.
Maintenance of mild to moderate bronchial asthma; treatment of itching caused by allergic conjunctivitis.
Standard considerations.
Aerosol inhalation 2 inhalations 4 times daily at regular intervals to provide 14 mg/day. May attempt lower frequency of doses in well-controlled patients.
Store at controlled room temperature (59° to 86°F).
None well documented.
None well documented.
Headache.
Ocular burning; irritation and stinging; unpleasant taste; nasal congestion; conjunctivitis; eye redness; photophobia.
Nausea; vomiting; dyspepsia; abdominal pain.
Rhinitis; upper respiratory tract infection; asthma.
Unpleasant taste.
Category B .
Undetermined.
Safety and efficacy in children younger than 6 yr of age not established (aerosol inhalation). Safety and efficacy in children younger than 3 yr of age not established (ophthalmic).
Do not use for reversal of acute bronchospasm, particularly status asthmaticus. However, continue to administer during acute exacerbations, unless patient becomes intolerant to inhaled dosage forms.
If cough or bronchospasm follow inhalation, may need to discontinue.
Optimal effect depends on administration at regular intervals, even during symptom-free periods.
Copyright © 2009 Wolters Kluwer Health.